EA201791333A1 - Производные глюкагона с улучшенной стабильностью - Google Patents
Производные глюкагона с улучшенной стабильностьюInfo
- Publication number
- EA201791333A1 EA201791333A1 EA201791333A EA201791333A EA201791333A1 EA 201791333 A1 EA201791333 A1 EA 201791333A1 EA 201791333 A EA201791333 A EA 201791333A EA 201791333 A EA201791333 A EA 201791333A EA 201791333 A1 EA201791333 A1 EA 201791333A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glucagon
- obesity
- present
- derivative
- improved stability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к новому пептиду - производному глюкагона и к композиции для предупреждения или лечения гипогликемии и ожирения, содержащей этот пептид в качестве активного ингредиента. Производное глюкагона по настоящему изобретению сохраняет активность в отношении рецепторов глюкагона и обладает улучшенными физическими свойствами благодаря измененной изоэлектрической точке (pl) и, таким образом, может улучшать соблюдение пациентом режима и схемы лечения при использовании в качестве лекарственного средства против гипогликемии, а также пригодно для введения в комбинации с другими лекарственными средствами против ожирения. Соответственно производное глюкагона по настоящему изобретению может быть эффективно использовано в предупреждении или лечении гипогликемии и ожирения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 | ||
| PCT/KR2015/014422 WO2016108586A1 (ko) | 2014-12-30 | 2015-12-30 | 안정성이 증가된 글루카곤 유도체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201791333A1 true EA201791333A1 (ru) | 2017-12-29 |
| EA035527B1 EA035527B1 (ru) | 2020-06-30 |
Family
ID=56284642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791333A EA035527B1 (ru) | 2014-12-30 | 2015-12-30 | Производные глюкагона с улучшенной стабильностью |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (ru) |
| EP (2) | EP3575314B1 (ru) |
| JP (2) | JP6797122B2 (ru) |
| KR (1) | KR102291020B1 (ru) |
| CN (1) | CN107636009B (ru) |
| AR (1) | AR103322A1 (ru) |
| AU (1) | AU2015372818A1 (ru) |
| CA (1) | CA2972748A1 (ru) |
| CL (1) | CL2017001718A1 (ru) |
| CO (1) | CO2017006308A2 (ru) |
| CR (1) | CR20170293A (ru) |
| DO (1) | DOP2017000156A (ru) |
| EA (1) | EA035527B1 (ru) |
| EC (1) | ECSP17040923A (ru) |
| GT (1) | GT201700150A (ru) |
| HK (1) | HK1248713A1 (ru) |
| IL (2) | IL253206B (ru) |
| MA (1) | MA40709B1 (ru) |
| MX (1) | MX2017008569A (ru) |
| MY (1) | MY185334A (ru) |
| NZ (1) | NZ733464A (ru) |
| PE (2) | PE20171154A1 (ru) |
| PH (1) | PH12017501222A1 (ru) |
| SG (1) | SG11201705376SA (ru) |
| TN (1) | TN2017000271A1 (ru) |
| TW (1) | TW201639878A (ru) |
| UA (1) | UA126960C2 (ru) |
| WO (1) | WO2016108586A1 (ru) |
| ZA (1) | ZA201705015B (ru) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696725B2 (en) | 2015-06-30 | 2020-06-30 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| US10981967B2 (en) | 2015-12-31 | 2021-04-20 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
| US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| US11142559B2 (en) | 2016-06-29 | 2021-10-12 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US20200230250A1 (en) | 2017-02-03 | 2020-07-23 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of a physiologically active material and use thereof |
| EA202091239A1 (ru) * | 2017-12-22 | 2020-09-09 | Ханми Фарм. Ко., Лтд. | Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение |
| MX2020007768A (es) * | 2018-01-23 | 2020-11-12 | Xeris Pharmaceuticals Inc | Tratamiento contra hipoglucemia posbariátrica usando pequeñas dosis de glucagón estable. |
| US20220064248A1 (en) | 2018-12-21 | 2022-03-03 | HANMl PHARM. CO., LTD | Pharmaceutical composition including insulin and glucagon |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| US20230192800A1 (en) | 2020-05-22 | 2023-06-22 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glucagon derivative |
| CN116096397A (zh) | 2020-07-15 | 2023-05-09 | 韩美药品株式会社 | 胰高血糖素衍生物或其缀合物对于肝脏疾病的治疗用途 |
| CN117157094A (zh) | 2021-04-09 | 2023-12-01 | 韩美药品株式会社 | 包括胰高血糖素衍生物的用于预防或治疗慢性肾病的药物组合物 |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| EP2275117B1 (en) | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| UA92451C2 (en) | 2003-03-19 | 2010-11-10 | Эли Лилли Энд Компани | Polyethelene glycol link glp-1 compounds |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| KR100775343B1 (ko) | 2003-11-13 | 2007-11-08 | 한미약품 주식회사 | 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물 |
| EP2573111A1 (en) | 2006-04-20 | 2013-03-27 | Amgen Inc. | GLP-1 compounds |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| ES2628063T3 (es) * | 2007-01-05 | 2017-08-01 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos |
| KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CN102015761A (zh) | 2007-06-19 | 2011-04-13 | 大塚化学株式会社 | 附加糖链的glp-1肽 |
| JP5476304B2 (ja) | 2007-09-05 | 2014-04-23 | ノボ・ノルデイスク・エー／エス | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| EP2300035B1 (en) | 2008-06-17 | 2015-08-12 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| EP2454282B1 (en) | 2009-07-13 | 2015-03-04 | Zealand Pharma A/S | Acylated glucagon analogues |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CA2786934A1 (en) * | 2010-01-20 | 2011-07-28 | Zealand Pharma A/S | Treatment of cardiac conditions |
| US20130143798A1 (en) * | 2010-03-26 | 2013-06-06 | Novo Nordisk A/S | Novel glucagon analogues |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN103458920B (zh) | 2010-12-22 | 2016-07-06 | 印第安那大学科技研究公司 | 表现出gip受体活性的胰高血糖素类似物 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| KR102255479B1 (ko) | 2011-05-18 | 2021-05-24 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| AU2012267398B2 (en) * | 2011-06-10 | 2016-10-13 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| RU2733544C2 (ru) * | 2011-06-17 | 2020-10-05 | Ханми Сайенс Ко., Лтд. | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| BR112014007124A2 (pt) * | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| EA029025B1 (ru) | 2012-06-21 | 2018-01-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EA039082B1 (ru) | 2012-11-06 | 2021-12-01 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
| CA2891929C (en) | 2012-11-20 | 2022-07-19 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR102365582B1 (ko) | 2012-11-20 | 2022-02-18 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| EP2934569A1 (en) | 2012-12-21 | 2015-10-28 | Sanofi | Exendin-4 derivatives |
| WO2014170496A1 (en) * | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| MA40709B1 (fr) | 2014-12-30 | 2019-07-31 | Hanmi Pharmaceutical Co Ltd | Dérivé du glucagon à stabilité améliorée |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| KR102005456B1 (ko) | 2015-06-30 | 2019-07-30 | 한미약품 주식회사 | 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물 |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| PE20181494A1 (es) | 2015-12-31 | 2018-09-18 | Hanmi Pharm Ind Co Ltd | Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 u gip |
-
2015
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
- 2015-12-30 NZ NZ733464A patent/NZ733464A/en unknown
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko active Application Filing
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
- 2015-12-30 CA CA2972748A patent/CA2972748A1/en active Pending
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active IP Right Grant
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
-
2017
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-06-29 PH PH12017501222A patent/PH12017501222A1/en unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2018
- 2018-04-10 HK HK18104685.2A patent/HK1248713A1/zh unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| US10696725B2 (en) | 2015-06-30 | 2020-06-30 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| US11261227B2 (en) | 2015-06-30 | 2022-03-01 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| US11667688B2 (en) | 2015-06-30 | 2023-06-06 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| US10981967B2 (en) | 2015-12-31 | 2021-04-20 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
| US11332508B2 (en) | 2015-12-31 | 2022-05-17 | Hanmi Pharm. Co., Ltd. | Triple glucagon/GLP-1/GIP receptor agonist |
| US11142559B2 (en) | 2016-06-29 | 2021-10-12 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| CY1124675T1 (el) | Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
| EA201590058A1 (ru) | Аналоги глюкагона | |
| EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
| MX368387B (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA201692392A1 (ru) | Новая лекарственная форма мелоксикама | |
| CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| TR201908936T4 (tr) | Opioidler ile kombinasyon halinde palmitoiletanolamid kullanımı. | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| EA201501130A1 (ru) | Офтальмологическая фармацевтическая композиция | |
| TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
| EA202191014A1 (ru) | Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства | |
| EA201791713A1 (ru) | Применение модифицированных полимеров глюкозы для снижения метастазирования опухолей | |
| UA111116C2 (uk) | Збалансований інфузійний розчин | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |